Signet Medical Solutions (OTC:SIGN) said today that it will license all rights to its non-invasive, vapor analysis system for detecting melanoma.
The technology is designed to operate in real time, using vapor samples for painless diagnoses without time delays, according to parent company Signet International Holdings (Palm Beach, Fla.).
Melanoma, along with other cancers, gives off distinct, detectable chemical compounds. The “smell” technology is meant to analyze skin odors to determine if biomarkers for melanoma are present in a patient.
Signet also said the patent is globally protected.
“It’s exciting to avail this technology to the medical industry,” Signet president Tom Donaldson said in prepared remarks. “It will be profitable to Signet shareholders. As a sufferer of this disease, I have experienced many biopsies. The current diagnostic method takes up to 10 days for results. Our technology is instantaneous; no stress waiting to find out if you have melanoma. We offer comfort to those who will no longer have to make appointments to be tested and then wait even longer to be informed of the results.
“We are excited to be on the threshold of commercializing this amazing technology; eliminate the ‘wait-and-watch’ approach,” Donaldson added. “‘Real-time’ is the essential word. With just a ‘whiff,’ our method will allow stress-free diagnosis and immediate treatment. This is a major win.”